Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil
Clinical trial NCT06231693 · TERMINATED
Trial details
- NCT number
- NCT06231693
- Sponsor
- AstraZeneca
- Status
- TERMINATED
- Study type
- OBSERVATIONAL
- Start date
- 2023-12-04
- Primary completion
- 2024-03-26
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.